- •Preface
- •Contents
- •Contributors
- •1: Living with Diabetic Retinopathy: The Patient’s View
- •My Patient Experience
- •Others’ Experiences
- •Photos of the Meaning of Diabetes
- •References
- •2: Diabetic Retinopathy Screening: Progress or Lack of Progress
- •Definitions of Screening for Diabetic Retinopathy
- •Studies Reporting the Prevalence of Diabetic Retinopathy
- •Reports on Blindness and Visual Impairment
- •Is There Evidence That Treatment for Sight-Threatening Diabetic Retinopathy Is Effective and Agreed Universally?
- •The Evidence That Diabetic Retinopathy Can Be Prevented or the Rate of Deterioration Reduced by Improved Control of Blood Glucose, Blood Pressure and Lipid Levels, and by Giving Up Smoking
- •The Evidence that Laser Treatment Is Effective
- •The Evidence That Vitrectomy for More Advanced Disease Is Effective
- •Progress of Lack of Progress in Screening for Diabetic Retinopathy in Different Parts of the World
- •References
- •3: Functional/Neural Mapping Discoveries in the Diabetic Retina: Advancing Clinical Care with the Multifocal ERG
- •Introduction
- •The Diabetes Epidemic
- •Current Treatment Focus
- •Vasculopathy and Neuropathy of the Retina
- •The Early Efforts
- •Some Breakthroughs
- •Predictive Models of Visible Retinopathy Onset at Specific Locations
- •How Is the mfERG Measured and What is it Measuring?
- •Where Are These Neural Signals Generated in the Retina?
- •Some Key Results
- •Adolescents and Adult Diabetes
- •Type 1 vs. Type 2: Differences in Retinal Function
- •References
- •4: Corneal Diabetic Neuropathy
- •Introduction
- •Corneal Confocal Microscopy
- •Corneal Nerves and Diabetes
- •Conclusion
- •References
- •5: Clinical Phenotypes of Diabetic Retinopathy
- •Natural History
- •MA Formation and Disappearance Rates
- •Alteration of the Blood–Retinal Barrier
- •Retinal Capillary Closure
- •Multimodal Macula Mapping
- •Clinical Retinopathy Phenotypes
- •Relevance for Clinical Trial Design
- •Relevance for Clinical Management
- •Targeted Treatments
- •References
- •6: Visual Psychophysics in Diabetic Retinopathy
- •Introduction
- •Visual Acuity
- •Color Vision
- •Contrast Sensitivity
- •Macular Recovery Function (Nyctometry)
- •Perimetry
- •Microperimetry (Fundus-Related Perimetry)
- •Conclusion
- •References
- •7: Mechanisms of Blood–Retinal Barrier Breakdown in Diabetic Retinopathy
- •The Protective Barriers of the Retina
- •The Inner and the Outer BRB
- •Inflammation and BRB Permeability
- •Leukocyte Mediators of Vascular Leakage
- •Other Mediators of Leukocyte Recruitment in DR
- •Structural Compromise of the BRB
- •Vascular Endothelial Growth Factor
- •Anti-VEGF Properties of Natriuretic Peptides
- •Proposed Model of BRB Breakdown in DR
- •Key Role of AZ in VEGF-Induced Leakage
- •Azurocidin Inhibition Prevents Diabetic Retinal Vascular Leakage
- •References
- •8: Molecular Regulation of Endothelial Cell Tight Junctions and the Blood-Retinal Barrier
- •The Blood-Retinal Barrier
- •The Retinal Vascular Barrier
- •The Junctional Complex
- •ZO Proteins
- •Claudins
- •Junctional Adhesion Molecules
- •Occludin and Tricellulin
- •Vascular Permeability in Diabetic Retinopathy
- •VEGF-Induced Regulation of Endothelial Permeability
- •Occludin Phosphorylation and Permeability
- •Protein Kinase C in Regulation of Barrier Properties
- •Conclusions
- •References
- •9: Capillary Degeneration in Diabetic Retinopathy
- •Vascular Nonperfusion in Diabetes: Mechanisms
- •Molecular Causes of Capillary Degeneration
- •Unexplained Aspects of Diabetes-Induced Degeneration of Retinal Capillaries
- •What Is the Relation Between the Retinal Vasculature and Neuronal Retina Structure and Function in Diabetes?
- •Conclusion
- •References
- •10: Proteases in Diabetic Retinopathy
- •Proteases in Retinal Vasculature
- •Extracellular Proteases
- •Urokinase Plasminogen Activator System (uPA/uPAR System)
- •Matrix Metalloproteinases
- •Endogenous Inhibitors of Proteases
- •Tissue Inhibitors of Metalloproteinases (TIMPs)
- •Plasminogen Activator Inhibitors (PAI)
- •Proteases in Retinal Neovascularization
- •Tissue Inhibitor of Matrix Metalloproteinases in Retinal Neovascularization
- •Inhibition of Retinal Angiogenesis by MMP Inhibitors
- •Inhibition of Retinal Angiogenesis by Inhibitors of the uPA/uPAR System
- •Proteases in Diabetic Macular Edema
- •Conclusion
- •References
- •11: Proteomics in the Vitreous of Diabetic Retinopathy Patients
- •Introduction
- •Vitreous Anatomy
- •A Candidate Approach
- •Proteomic Approaches
- •Vitreous Acquisition
- •Sample Pre-Fractionation
- •Mass Spectrometry
- •Spectral Analysis
- •Data Analysis
- •The Vitreous Proteome
- •2-DE-Based Proteomics
- •1-DE-Based Proteomics
- •Summary and Conclusions
- •References
- •12: Neurodegeneration in Diabetic Retinopathy
- •Introduction
- •Histological Evidence
- •Early Pathology Studies
- •Histological Evidence of Apoptosis
- •Gross Morphological Changes in the Retina
- •Reductions in Numbers of Surviving Amacrine Cells
- •Retinal Ganglion Cell Loss
- •Abnormalities in Ganglion Cell Morphology
- •Centrifugal Axon Abnormalities
- •Nerve Fiber Layer Thickness
- •Biochemical Evidence of Neurodegeneration and Cell Death
- •Functional Evidence of Neurodegenerative Changes
- •Electrophysiological Evidence for Neurodegeneration
- •Optic Nerve Retrograde Transport
- •Other Changes in Visual Function
- •Summary and Conclusions
- •References
- •13: Glucose-Induced Cellular Signaling in Diabetic Retinopathy
- •Introduction
- •Cellular Targets in DR
- •Endothelial Cell (EC) Dysfunction
- •Endothelial-Pericyte Interactions
- •Endothelial-Matrix Interactions
- •Signaling Mechanisms in DR
- •Altered Vasoactive Factors
- •Alteration of Metabolic Pathways
- •Polyol Pathway
- •Hexosamine Pathway
- •Protein Kinase C Pathway
- •Activation of Other Protein Kinases
- •Mitogen-Activated Protein Kinase (MAPK)
- •Increased Oxidative Stress
- •Protein Glycation
- •Aberrant Expression of Growth Factors
- •Transcription Factors
- •Transcription Regulators
- •Concluding Remarks
- •References
- •Introduction
- •The Growth-Hormone/Insulin-Like Growth Factor Pathway in Proliferative Retinopathies
- •Proliferative Diabetic Retinopathy (PDR)
- •Retinopathy of Prematurity (ROP)
- •Animal Models of Proliferative Retinopathies
- •IGFBP-3 as a Regulator of the Growth-Hormone/ Insulin-Like Growth Factor Pathway
- •Conclusion
- •References
- •15: Neurotrophic Factors in Diabetic Retinopathy
- •Diabetic Retinopathy
- •Neurotrophic Factors
- •Neurotrophins and Others
- •Nerve Growth Factor
- •Glial-Cell-Derived Neurotrophic Factor
- •Ciliary Neurotrophic Factor
- •Anti-angiogenic Neurotrophic Factors
- •Pigment-Epithelium-Derived Factor
- •SERPINA3K
- •Brain-Derived Neurotrophic Factor
- •Fibroblast Growth Factors
- •Insulin and Insulin-Like Growth Factor 1
- •Erythropoietin
- •Vascular Endothelial Growth Factor
- •Neurotrophic Factors and the Future of DR Research
- •References
- •16: The Role of CTGF in Diabetic Retinopathy
- •Introduction
- •ECM Remodeling and Wound Healing Mechanisms in Diabetic Retinopathy
- •ECM Remodeling in PCDR
- •Wound Healing Mechanisms in PDR
- •CTGF Structure and Function
- •CTGF in the Eye
- •CTGF in Ocular Fibrosis
- •CTGF in Ocular Angiogenesis
- •CTGF in Diabetic Retinopathy
- •CTGF in BL Thickening in PCDR
- •AGEs and CTGF in BL Thickening in PCDR
- •Role of VEGF in BL Thickening
- •BL Thickening in Diabetic CTGF-Knockout Mice
- •CTGF in PDR
- •Role of CTGF and VEGF in the “Angiofibrotic Switch” in PDR
- •Conclusions
- •References
- •17: Ranibizumab and Other VEGF Antagonists for Diabetic Macular Edema
- •Introduction
- •Pathogenesis of DME and Current Standard of Care
- •Ranibizumab for DME
- •Pegaptanib for DME
- •Bevacizumab for DME
- •VEGF Trap-Eye for DME
- •Other Considerations in the Management of DME
- •Combination Treatment for DME
- •DME and Quality of Life
- •Conclusions
- •References
- •18: Neurodegeneration, Neuropeptides, and Diabetic Retinopathy
- •Introduction
- •Neuropeptides Involved in the Pathogenesis of DR
- •Glutamate
- •Angiotensin II
- •Pigment Epithelial-Derived Factor
- •Somatostatin
- •Erythropoietin
- •Docosahexaenoic Acid and Neuroprotectin D1
- •Brain-Derived Neurotrophic Factor
- •Glial Cell Line-Derived Neurotrophic Factor
- •Ciliary Neurotrophic Factor
- •Adrenomedullin
- •Concluding Remarks and Therapeutic Implications
- •References
- •19: Glial Cell–Derived Cytokines and Vascular Integrity in Diabetic Retinopathy
- •Introduction
- •The BRB Functional Unit Composed of Glial and Endothelial Cells
- •Tight Junctions Between Endothelial Cells Are Substantial Barrier of the BRB
- •Major Cytokines Derived from Glial Cells Affecting Tight Junctions of the BRB
- •VEGF
- •GDNF
- •APKAP12
- •A Possible Treatment of the Retinopathy with Retinoic Acid Analogues
- •Conclusion
- •References
- •20: Impact of Islet Cell Transplantation on Diabetic Retinopathy in Type 1 Diabetes
- •Introduction
- •What Are the Benefits and Risks of Reducing Blood Glucose?
- •On Average, 3 Years Was Required to Demonstrate the Beneficial Effect of Intensive Treatment
- •The Earlier in the Course of Diabetes That Intensive Therapy Is Initiated, Even Before the Onset of Retinopathy, the Greater the Long-Term Benefits
- •Risk Reduction in the Primary Prevention Cohort
- •Risk Reduction in the Secondary Prevention Cohort
- •There Was No Glycemic Threshold Regarding Progression of Retinopathy
- •Diabetic Ketoacidosis (DKA)
- •Efforts to Normalize Blood Glucose Are Associated with Weight Gain in People with Type 1 Diabetes
- •Connecting Peptide (C-Peptide) Responders Have Less Risk of Progression of Retinopathy
- •Effects of Improved Control on Retinopathy Were Sustained in the Long-Term
- •Quality of Life Measure
- •“Metabolic Memory”: A Phenomenon Producing a Long-Term Beneficial Influence of Early Metabolic Control on Clinical Outcomes
- •Need for a More Physiologic Glycemic Control Regimen
- •Effect of Intensive Insulin Therapy on Hypoglycemia Counterregulation
- •b Cell Function
- •Whole Pancreas Transplantation
- •Effect of SPK Transplantation on Diabetic Retinopathy
- •Islet Cell Transplantation
- •Adverse Effects of Chronic Immunosuppression
- •Effect of Islet Cell Transplantation on Retinopathy
- •References
- •Index
12 |
Stuckey |
healing, even if not a cure. Even if we don’t understand all the root causes of diabetes or retinopathy, as patients, we can reflect on what we do know and how we can help others live more fully with the disease. As medical professionals, researchers, and scientists, that fear is something we can seek to eliminate.
PHOTOS OF THE MEANING OF DIABETES
To put these thoughts of the diagnosis and the meaning of diabetes in visual form, the photo below represents the day of my diabetes diagnosis (Fig. 3). It is labeled “unnatural” because having diabetes meant I would need to take some form of insulin injection every day for the rest of my life and should avoid sugar. I might go blind when I grow older or lose my kidney function. These things are unnatural, especially as a young child, represented by the bright orange slash. The slash appears among the ground and the grass of the earth, meaning growth and natural life. Although originally, the photo was about the diagnosis of diabetes, it also relates to its complications, such as retinopathy. Having retinal surgery is unnatural, as some blood vessels are sacrificed in order to save others and to preserve the site for long term. Although some eye procedures can be expected at an older age, it is unnatural, and frightening, to have surgery at age 25.
This next photo (Fig. 4) of a cell block also represents my thoughts of having diabetes and diabetic retinopathy. I took this picture at the Eastern State Penitentiary in Philadelphia, Pennsylvania. As the website states (http://www.easternstate.org/), the Penitentiary was once the most famous and expensive prison in the world, but stands today as a world of crumbling cellblocks and empty guard towers. My eyes used to be unscathed by disease, but have slowly deteriorated, like the plaster on the floor of the cell and the table that has fallen down from the weight of gravity over the years. My eyes show
Fig. 3. Unnatural.
Living with Diabetic Retinopathy |
13 |
Fig. 4. Hydrant.
evident signs of damage in the pin-points of burning laser that penetrated my retina, and my lack of peripheral vision.
The room (and my sight) is not gone, however, because the building has not collapsed. The structure remains intact. Although my eyes may be ragged and somewhat worn out, they still perform the job that they were intended to do. I can see. I realize the room will not be restored to complete newness, but it can be cleaned and maintained. Keeping my diabetes under control and my body healthy, there’s hope that I will be able to see for my lifetime.
It is a wonderful thing to have vision, to experience life in color, to read, to watch the clouds move mysteriously on an overcast day, and to be able to turn my head and see my son when he was younger, yelling, “Watch this, mom,” from the playground. As he gets older, my eyes soak in the shape of his face and the curl of his hair and study the speckles of light in his eyes. I can see, and my prognosis for continued vision is very good. Each year, I schedule an appointment with Dr. Gardner, and my eyesight remains stable.
Rather than destroying the retina and damaging vision, we need to find easier, gentler ways to treat diabetic retinopathy to detect ways of catching the disease earlier so the fear of blindness is much less. That is what is important to us who have retinopathy. But scientific research to find a less destructive treatment is only part of the story. Behind every project or procedure, there’s a human element––a person who is frightened, wondering whether he’s going to go blind. He’s giving his eyes, one of his most valuable possessions to you, the clinician. Besides vessels and fluid, what do you see? Do you see the way they are looking at you for hope? Do you see how they are afraid that they might go blind? They don’t want to go through laser treatment. They are afraid there will be complications with the surgery, and they will go blind. They won’t remember the hue of the sky or the color of the cornfield. What did snow really look like? And what did the shadow of my toddler’s head look like at night? This person with diabetic retinopathy might go blind. And they are looking to you for hope. Regardless of your relationship
14 |
Stuckey |
to research, there is a patient, not a retina, who needs hope. What do you see? How can you give them that hope? How can you communicate trust to them? The best advice I can give is to look them with a soft face and tell them that you are going to do whatever it takes to preserve their sight. Their probability for continued eyesight is going to be very good. There are other promising methods for treatment, and you will make sure that they are getting the best treatment possible. This is really seeing. How can you improve your eyesight, your communication of hope to the patient? If you give me laser surgery treatment, you’re treating maybe half of my disease. But if you give me hope that I won’t go blind, you treat the other half.
Perhaps some of you have diabetes, or have loved ones and friends who have a chronic illness, or have diabetic retinopathy. This personal connection is what stirred you. Maybe your interest also comes from a deep desire to improve the lives of so many who suffer with diabetes and its complications or the science of discovering a cure or a breakthrough in treatment. For me, understanding the experience of diabetes is not only a research interest, but a personal quest. My hope is that you will see what having diabetes, and diabetic retinopathy, means to someone with diabetes, and you will understand how very important your work is to those of us who have this chronic illness.
The research in this book is groundbreaking and exciting. Research like this has preserved the eyesight of myself and many others and improved our quality of life. Over the past 20 years, I have seen many outstanding medical achievements in diabetes care: blood glucose machines, which achieve accurate results in 5 s, short-acting human insulin, needles which come in ultrathin shapes and sizes, and the insulin pump, continuous glucose monitoring and new advances in knowledge, medication, and technology that have made it possible for people with diabetes to live long, productive lives.
Ultimately, I hope we will be able to find a cure for diabetes. Diabetes is a demanding, frightening, exasperating disease. I fully support research that finds ways to make it easier to live with the complications of diabetes. As a fellow researcher, a patient, and as a friend, I thank all of you reading this chapter who have worked to preserve our eyesight, in whatever way. I encourage you to continue to find research to improve the lives of those with diabetic retinopathy, not only to restore sight but also to give hope.
REFERENCES
1. Charon R, Spiegel M (2006) Reflexivity and responsiveness: the expansive orbit of knowledge. Lit Med 51:vi–xi
2. Charon R (2004) Narrative and medicine. New Engl J Med 350(9):862–865
3. Charon R (2001) Narrative medicine: a model for empathy, reflection and trust. J Am Med Assoc 286(15):1897–1902
4. Charon R (2004) Physician writers: Rita Charon. Lancet 363(9406):404
5. Stuckey H, Tisdell E (2010) The role of creative expression in diabetes: an exploration into the meaning-making process. Qual Health Res 20:42–56
6. Stuckey H (2009) Creative expression as a way of knowing in diabetes adult health education: an action research study. Adult Educ Q 60:46–64
Part II
How Is Diabetic Retinopathy Detected?
